Royalty Pharma
Royalty Pharma

Transforming the Funding
of Life Sciences Through
Collaborative Capital

Transforming the Funding of Life Sciences Through Collaborative Capital

Engage With Us

We work directly with innovators across
the life sciences, including research
institutions, inventors, and biopharma
companies.

Our Approach
Home Engage
Royalty Monetization

APPROVED PRODUCT ROYALTY MONETIZATION

The biopharmaceutical industry is undergoing a period of strong growth and unprecedented innovation. We intend to further this innovation by acquiring royalties on leading biopharmaceutical products.

Read More

DEVELOPMENT CANDIDATES

We seek to acquire royalties on innovative product candidates in the late-stages of clinical development. We collaborate directly with innovators to acquire a new synthetic royalty, monetize an existing royalty or provide capital to an innovator to co-fund clinical development of a product candidate in exchange for a royalty.

Read More
R&D Partnership
M&A

M&A

We take a flexible approach to acquisitions. In biopharmaceutical acquisitions, the focus of an acquirer is typically on strategic assets over which the target has operational control, rather than on passive financial assets such as royalties. We can partner with strategic acquirers which buy companies that own both strategic assets and passive royalties.

Read More